Mankind Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Rivotril, the innovator/reference brand of clonazepam, is widely prescribed for the management of neurological and psychiatric conditions. Known as a textbook brand with a strong clinical legacy, the acquisition reinforces Mankind Pharma?s presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio.

The move aligns with Mankind Pharma?s growing focus on chronic therapies, an area where the company has expanded steadily through new product launches, in-licensing partnerships, and portfolio additions across key therapeutic areas. Chronic therapies now contribute an increasing share to the company?s overall business, enabling deeper engagement with specialists and key opinion leaders.

Atish Majumdar, senior president, sales & marketing, Mankind Pharma Specialty Business, said, ?This acquisition is aligned with our strategic focus on strengthening our presence in chronic and specialty therapies. We see strong opportunities to build on this platform through potential line extensions, addressing the evolving needs of patients and physicians in the CNS therapy area. Leveraging our large field force and nationwide distribution network, we are well positioned to build the brand and support physicians in delivering better outcomes for patients across India.?

Mankind Pharma plans to utilize its extensive distribution network and field force to expand access to Rivotril across healthcare institutions and prescribers. The company currently engages with over 5 lakh doctors in India, enabling strong prescription penetration across urban and semi-urban markets.

Mankind Pharma is one of India?s largest pharmaceutical companies, operating with a pan-India presence. The company manufactures a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow-fill-seal products, soft and hard gels, eye drops, creams, contraceptives, and other over-the-counter products across 32 manufacturing facilities. It also maintains six dedicated R&D centers with more than 730 scientists, supporting a consistent track record of product innovation.

The company reported a 7.5% rise in consolidated net profit of Rs 408.75 crore in Q3 FY26 as against Rs 380.23 crore posted in Q3 FY25. Net sales fell 11.5% YoY to Rs 3,567.20 crore in the quarter ended 31 December 2025.

Powered by Capital Market - Live News

Mankind Pharma has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. Often regarded as a Textbook brand in its category with a strong clinical legacy, Rivotril further strengthens Mankind Pharma's presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio.

The acquisition builds on Mankind Pharma's growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Chronic therapies now account for a rising share of the company's overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders. Furthermore, the addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions.

Powered by Capital Market - Live News

Mankind Pharma has allotted 23,256 equity shares under ESOP on 16 March 2026. Post allotment, the paid up equity share capital has increased to 41,28,28,328 equity shares having face value of Re 1/- each.

Powered by Capital Market - Live News

Mankind Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2113.1, up 2.84% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 25467.85. The Sensex is at 82264.76, up 0.05%. Mankind Pharma Ltd has gained around 0.9% in last one month.

Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 5.38% in last one month and is currently quoting at 22632.05, up 1.45% on the day. The volume in the stock stood at 3.22 lakh shares today, compared to the daily average of 3.54 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 2126.3, up 2.78% on the day. Mankind Pharma Ltd is down 7.89% in last one year as compared to a 12.96% jump in NIFTY and a 13.66% jump in the Nifty Pharma index.

The PE of the stock is 47.98 based on TTM earnings ending December 25.

Powered by Capital Market - Live News